
NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced new preclinical data showing that NUC-7738 enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor used to treat patients with multiple myeloma. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18–20, 2026.
Carfilzomib works by inhibiting the proteasome, a cellular system that breaks down unwanted proteins. Multiple myeloma cells depend heavily on this system to manage their high protein load. NuCana believes that increasing the effectiveness of proteasome inhibition could make these cancer cells more vulnerable to treatment.
In three multiple myeloma cell lines, NUC-7738 demonstrated single-agent activity and increased the anti-cancer activity of carfilzomib. At concentrations where the individual agents left approximately half of the cells viable, the combination reduced cell viability to 3% in two models and 26% in the third after 96 hours. In two of the three models, the combination’s activity exceeded that expected if the two agents acted independently; in the third, the effect was additive. These findings provide a scientific rationale for NuCana to further investigate the combination in multiple myeloma.
Further studies showed that NUC-7738 altered proteasome function and increased the inhibition achieved with carfilzomib. In one model, proteasome activity after 24 hours was 25% of the untreated control with the combination, compared with 52% with carfilzomib alone. NuCana believes this demonstrates a measurable effect on the cellular system targeted by carfilzomib and may help explain the combination’s greater anti-cancer activity.
NuCana believes the findings also suggest an additional potential mode of action for NUC-7738. Although NUC-7738 initially increased proteasome activity when used on its own, it also reduced the processed form of NFE2L1, a protein involved in the cellular response to proteasome inhibition. Our research proposes that NUC-7738’s active metabolite may influence the opening of the proteasome’s gate, potentially increasing access for carfilzomib. These observations offer a basis for investigating how NUC-7738 may increase cancer cells’ sensitivity to proteasome inhibitors. Further studies are needed to test this proposed mode of action and assess its relevance to treatment in patients.
NuCana believes these results also support further investigation beyond multiple myeloma. In a separate laboratory screen evaluating NUC-7738 with 70 partner drugs across 35 cancer cell lines, carfilzomib ranked first on a measure of greater-than-expected combination activity. Such activity was observed in 28 of 33 solid-tumor models spanning 14 tumor types, at a single concentration of NUC-7738. These findings highlight the broad anti-cancer potential of NUC-7738 and supports further evaluation to identify the cancer indications in which the combination may offer the greatest potential.